Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lusky

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
The Journal of Gene Medicine|February 24, 2001
Differential influence of the E4 adenoviral genes on viral and cellular promotersL Grave, D Dreyer, A Dieterle, et al.
Oncotargets and Therapy|May 13, 2017
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytesB Heinrich, J Klein, M Delic, et al.
Journal of Virology|March 14, 1998
In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deletedM Lusky, M Christ, K Rittner, et al.
Cytotechnology|November 13, 2008
Gene transfer into canine myoblastsS Braun, C Thioudellet, F Perraud, et al.
Human Gene Therapy|March 4, 2000
Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene productsM Christ, B Louis, F Stoeckel, et al.
Journal of Virology|September 11, 1999
Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3M Lusky, L Grave, A Dieterlé, et al.
Human Gene Therapy|February 15, 2001
Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis gene therapyS Lerondel, A Le Pape, C Sené, et al.
Oncoimmunology|August 16, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)M Moehler, J Heo, H C Lee, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
The Journal of Gene Medicine|February 24, 2001
Differential influence of the E4 adenoviral genes on viral and cellular promotersL Grave, D Dreyer, A Dieterle, et al.
Oncotargets and Therapy|May 13, 2017
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytesB Heinrich, J Klein, M Delic, et al.
Journal of Virology|March 14, 1998
In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deletedM Lusky, M Christ, K Rittner, et al.
Cytotechnology|November 13, 2008
Gene transfer into canine myoblastsS Braun, C Thioudellet, F Perraud, et al.
Human Gene Therapy|March 4, 2000
Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene productsM Christ, B Louis, F Stoeckel, et al.
Journal of Virology|September 11, 1999
Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3M Lusky, L Grave, A Dieterlé, et al.
Human Gene Therapy|February 15, 2001
Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis gene therapyS Lerondel, A Le Pape, C Sené, et al.
Oncoimmunology|August 16, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)M Moehler, J Heo, H C Lee, et al.
Pageof 7